For Industry Sponsors and Collaborators

Why Partner with PSI?

The Psychedelic Science Institute (PSI) is a research-driven clinical organization dedicated to exploring how psychedelic medicines, as neuroplastogens, can help transform mental health care and neuroscience. Our TRIP Clinics are owned and led by highly experienced clinician-scientists and equipped with FDA-grade infrastructure to support rigorous, compliant and safe psychedelic research.

We’re more than just a trial site—we’re a collaborative partner in advancing both the science and humanity of psychedelic medicine.

Therapeutic Focus Areas

PSI focuses on advancing treatment options for some of the most urgent and under-resourced mental health and neuroscience conditions. Our teams specialize in conducting clinical trials and delivering care across a wide range of indications that align with sponsor and public health priorities including the following:

Anxiety

Bipolar Disorder

Depression

OCD

Traumatic Stress

We welcome sponsors advancing treatments for these and related conditions such as neurodegenerative conditions, traumatic brain injury, stroke, adjustment disorder, grief, and chronic pain.

Clinical Trial Capabilities

PSI is purpose-built to support the design, launch, and execution of psychedelic clinical trials. Our facilities and clinical team are structured to meet regulatory and operational demands while maintaining a deeply human-centered care model.

PSI offers:

Two operating clinical sites in Los Angeles (Santa Monica & Hollywood)
Comfortable and accessible dosing suites and private preparation/integration rooms
EMR + CTMS infrastructure
Supervised sessions by licensed, psychedelic-trained clinicians
IRB-experienced staff with high protocol fidelity
Rapid site start-up and sponsor collaboration readiness

Our team has supported Phase 2 and Phase 3 trials for psilocybin, LSD, MDMA, DMT, and ketamine in partnership with Usona, Compass Pathways, MindMed, Lykos, Reunion, Atai and more.

Current Trials Enrolling or in Start-up at PSI

TRIP Clinic Santa Monica:

Major Depression: Usona - Psilocybin Phase 3
Treatment Resistant Depression: atai - DMT Phase 2
Major Depression: MindMed - LSD Phase 3
Generalized Anxiety Disorder: MindMed - LSD Phase 3

TRIP Clinic Hollywood:

Major Depression: Cybin - Psilocybin analog Phase 3
Generalized Anxiety Disorder: MindMed - LSD Phase 3

Clinical Trials Completed by PSI Team

The two partner clinics (formerly PNI TRIP Center in Santa Monica and CCPT in Hollywood) have completed the following trials over the last 5 years:

Major Depression: Compass Pathways Phase 3 /COMP005 (2023-25)
Major Depression: Usona Psilocybin Phase 2 (2023)
Generalized Anxiety Disorder: MindMed LSD Phase 2 (2023)
PTSD: Lykos - MDMA-Assisted Therapy Phase 3 /MAPP1 & MAPP2 (2022-23): open label extension
Alcohol Use Disorder: PNI-funded trial - Psilocybin Phase 2 (2022)
PTSD: USC/Lykos Epigenetic regulation and MDMA-Assisted Psychotherapy (2021)
PTSD: Lykos/MAPS Public Benefit Corporation - MDMA- Assisted Therapy Phase 2 (2018)

Participant-Centered Design

At PSI, clinical rigor and patient dignity go hand in hand. We apply a participant-first lens to all aspects of trial delivery, ensuring every clinical trial protocol is carefully adhered to with patient safety as our top priority.

We don't just enroll participants—we retain and support them. Our model includes:

Culturally responsive outreach
Over 69% BIPOC and 29% LGBTQIA+ trial representation at our Hollywood site
Clarity in consent and post-trial continuity

This design drives trust, reduces dropout, and delivers meaningful real-world data.

Who We Collaborate With

PSI is built to support partnerships with diverse collaborators across the psychedelic and neuroscience ecosystems. Whether you're developing compounds, managing trials, or seeking integrated care pathways, PSI is structured to meet your needs.

We are actively seeking collaborations with:

Biotech & Pharma developing psychedelic or neuroplasticity-focused compounds
CROs managing trials and seeking experienced, staffed sites
Academic Institutions running investigator-initiated or translational research
Public Health Entities including NIH, VA, and DAF-aligned initiatives
Health Systems & Payers exploring integration or reimbursement of PAT

Past & Current Research Partners

Our proven track record includes collaborations with industry leaders across the psychedelic research field. These partnerships reflect our commitment to trial excellence, participant safety, and clinical innovation.

Our partners to date include:

Compass Pathways
Usona Institute
Mind Medicine
Lykos Therapeutics (MAPS PBC)
Reunion Neuroscience
Atai Life Sciences
Beckley Psytech

Peer-Reviewed Publications by PSI Team

Explore published studies, results, and peer-reviewed insights from our team and the clinical trials in which we have participated. Our goal is to advance the field with transparency and data, not promises.